Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous subcutaneous lidocaine for neuropathic cancer pain
ACTRN12617000747325Phase 2Not yet recruiting
- Sponsor
- University of Technology Sydney
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Neuralgia and cancer comparing Lidocaine continuous subcutaneous infusion with Placebo saline continuous subcutaneous infusion (2 arms). Primary endpoint: Completion rate of study medication and procedures. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
lidocaine
03
Conditions
Neuralgiacancer
Beyond the preview
Go deeper on ACTRN12617000747325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000747325.